(-1.04%) 5 062.74 points
(-1.16%) 37 942 points
(-1.23%) 15 786 points
(-1.16%) $81.67
(-2.61%) $1.977
(-2.31%) $2 303.30
(-3.76%) $26.62
(-1.50%) $947.10
(0.46%) $0.937
(1.03%) $11.10
(0.48%) $0.800
(0.16%) $93.45
@ $0.562
Utstedt: 12 feb 2024 @ 17:22
Avkastning: -23.29%
Forrige signal: feb 7 - 17:41
Forrige signal:
Avkastning: 4.13 %
Live Chart Being Loaded With Signals
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults...
Stats | |
---|---|
Dagens volum | 113 083 |
Gjennomsnittsvolum | 588 948 |
Markedsverdi | 12.80M |
EPS | $-22.40 ( 2024-03-10 ) |
Neste inntjeningsdato | ( $0 ) 2024-06-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0.110 |
ATR14 | $0.00100 (0.23%) |
Volum Korrelasjon
Redhill Biopharma Ltd Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
TTCF | 0.968 |
LNSR | 0.963 |
VIRX | 0.961 |
WISA | 0.959 |
IMRX | 0.957 |
NOTV | 0.956 |
IMCC | 0.955 |
SRZN | 0.955 |
SNCE | 0.954 |
FATE | 0.95 |
10 Mest negative korrelasjoner | |
---|---|
MGI | -0.956 |
CCRC | -0.944 |
PWOD | -0.942 |
STIM | -0.937 |
NWFL | -0.935 |
IMMR | -0.933 |
ROST | -0.93 |
HZNP | -0.929 |
ACAHU | -0.924 |
EWEB | -0.924 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Redhill Biopharma Ltd Korrelasjon - Valuta/Råvare
Redhill Biopharma Ltd Økonomi
Annual | 2023 |
Omsetning: | $6.51M |
Bruttogevinst: | $3.06M (47.03 %) |
EPS: | $3.68 |
FY | 2023 |
Omsetning: | $6.51M |
Bruttogevinst: | $3.06M (47.03 %) |
EPS: | $3.68 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Omsetning: | $61.80M |
Bruttogevinst: | $28.46M (46.06 %) |
EPS: | $-38.27 |
Financial Reports:
No articles found.
Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.